ClinicalTrials.gg
CompletedNCT04416386Updated Jul 26, 2022

Vitamin C Level Effect in Orthognathic Surgery

An observational study in Maxillofacial Abnormalities, Maxillofacial Injuries and Maxillofacial Trauma, sponsored by Medipol University. Completed at 1 site in Turkey. Open to participants aged 19 Years to 38 Years. Per ClinicalTrials.gov, last updated 2022-07-26.

Sponsored by Medipol University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
30
Ages
19 Years to 38 Years
Sex
All
01

Study summary

Comparing the pre and post-operative blood plasma levels of vitamin C according to oxidative stress and investigate the correlation between post-operative analgesia requirement and vitamin C levels following orthognathic surgery.

Read the detailed description

Vitamin C (ascorbic acid) is a water-soluble vitamin that has many functions include antioxidant, neuroprotective, neuromodulator and co-factor for various enzymes or chemical reactions. Primarily ascorbic acid is the most potent non-enzymatic antioxidant agent in an extracellular fluid which is crucial for defense against oxidative stress. Recent clinical studies have shown that trauma or surgery may lead to oxidative stress and plasma vitamin C level decreases due to body demand that most likely caused by oxidative stress.

Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage. One of the major purposes in the management of post-operative pain is to minimize the dose of medications to reduce side effects while providing adequate analgesia.

In orthopedic surgery and management of postherpetic neuralgia oral vitamin C supplementation significantly reduced pain. However, the decrease in vitamin C concentration,the effects on antinociception and postoperative pain are not fully understood.

In this study, investigators aimed to compare pre and post-operative blood plasma levels of vitamin C after orthognathic surgery and investigate a correlation between post-operative analgesia requirement and vitamin C levels without vitamin C administration.

02

Conditions studied

  • Maxillofacial Abnormalities
  • Maxillofacial Injuries
  • Maxillofacial Trauma
03

In context

Maxillofacial Abnormalities

21 studies on the registry are indexed under Maxillofacial Abnormalities; 2 are open to participants now.

Browse Maxillofacial Abnormalities studies →

Lead sponsor

Medipol University is the lead sponsor of 326 studies on the registry; 88 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 38 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Orthognathic surgery patients aged between 19-38 years (mean age 27.17) with ASA I and ASA II status will be included in this randomized prospective study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ASA) classification I-II
  • Scheduled for orthognatic surgery under general anesthesia

Exclusion criteria

Exclusion Criteria:

  • history of bleeding diathesis,
  • receiving anticoagulant treatment,
  • known local anesthetics and opioid allergy,
  • infection of the skin at the site of the needle puncture,
  • pregnancy or lactation,
  • patients who do not accept the procedure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Interventions

  • OtherVitamin C

    Pre and post-operative blood plasma levels of vitamin C will be investigated

06

What researchers measure

Primary outcomes

  1. Blood plasma levels of vitamin C

    Pre and post-operative blood plasma levels of vitamin C

    Time frame: Change from baseline blood plasma levels of vitamin C at postoperative 1, 2, 4, 8, 16 hours

Secondary outcomes

  1. Opioid consumption

    Postoperative opioid consumption

    Time frame: Change from baseline opioid consumption levels at postoperative 1, 2, 4, 8, 16 hours

07

Study locations

1 site
  • Istanbul Medipol University Hospital
    Istanbul, Bagcilar 34070, Turkey
08

References and documents

Publications

  • Fukushima R, Yamazaki E. Vitamin C requirement in surgical patients. Curr Opin Clin Nutr Metab Care. 2010 Nov;13(6):669-76. doi: 10.1097/MCO.0b013e32833e05bc. PubMed 20689415 ↗
  • Jeon Y, Park JS, Moon S, Yeo J. Effect of Intravenous High Dose Vitamin C on Postoperative Pain and Morphine Use after Laparoscopic Colectomy: A Randomized Controlled Trial. Pain Res Manag. 2016;2016:9147279. doi: 10.1155/2016/9147279. Epub 2016 Oct 30. PubMed 27872555 ↗
  • Pirbudak L, Balat O, Cekmen M, Ugur MG, Aygun S, Oner U. Effect of ascorbic acid on surgical stress response in gynecologic surgery. Int J Clin Pract. 2004 Oct;58(10):928-31. doi: 10.1111/j.1742-1241.2004.00022.x. PubMed 15587771 ↗

Individual participant data

Plan to share: No — We will not plan to share IPD

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Mar 2022, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2020
First posted
Jun 4, 2020
StartActual
Jun 13, 2020
Primary completionActual
Mar 30, 2022
CompletionActual
Mar 30, 2022
Last update
Jul 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04416386
Lead sponsor
Medipol University
Responsible party
Bahadir Ciftci (Principal Investigator, Medipol University) — Principal investigator
First posted
Jun 4, 2020
Start date
Jun 13, 2020
Primary completion
Mar 30, 2022
Completion
Mar 30, 2022
Last update
Jul 26, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion